Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12069200 | 0.98 | KMT2A (0.68) | KMT2AAXLHPGDSCDK2PDE10A | |
| SCHEMBL19654457 | 0.93 | KMT2A (0.55) | KMT2AAXLHPGDSADORA3ADORA1 | |
| SCHEMBL21593674 | 0.86 | KMT2A (0.49) | KMT2AAXLHPGDSADORA3ADORA1 | |
| SCHEMBL12067756 | 0.86 | MAPK1 (0.50) | KMT2AAXLPDE10AADORA3 | |
| SCHEMBL1783841 | 0.86 | KMT2A (0.49) | KMT2AAXLHSD17B10MEN1 | |
| SCHEMBL21593675 | 0.86 | KMT2A (0.49) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL21593576 | 0.84 | KMT2A (0.48) | KMT2AAXLCDK2ADORA3ADORA1 | |
| SCHEMBL1934159 | 0.83 | KMT2A (0.69) | KMT2AAXLHPGDSPDE10AKDM4E | |
| SCHEMBL21593640 | 0.82 | KMT2A (0.44) | KMT2AAXLADORA3ADORA1ADORA2A | |
| SCHEMBL1937546 | 0.81 | KMT2A (0.71) | KMT2AAXLHPGDSPDE10AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756805-A | Pteridinone derivatives as RSK inhibitors and their use | 华东师范大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-117384160-A | Compounds as CDK inhibitors and uses thereof | 华东理工大学 | 2024-01-12 | — | — | CN | disclosed |
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2022-05-12 | — | — | US | disclosed |
| CN-111217815-B | Compound containing pteridinone skeleton and preparation method and application thereof | 沈阳药科大学 | 2021-06-18 | — | — | CN | disclosed |
| CN-111484495-B | Preparation method and application of derivative containing dihydropteridine diketone framework | 沈阳药科大学 | 2021-06-01 | — | — | CN | disclosed |
| WO-2020185738-A1 | HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2020-09-17 | — | — | WO | disclosed |
| CN-111484495-A | Preparation method and application of derivative containing dihydropteridine diketone framework | 沈阳药科大学 | 2020-08-04 | — | — | CN | disclosed |
| CN-111217815-A | Compound containing pteridinone skeleton and preparation method and application thereof | 沈阳药科大学 | 2020-06-02 | — | — | CN | disclosed |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | KMT2A 3089/4885AXL 879/4885HPGDS 3637/4885 |
| US-20230172940-A1 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | GPX4, GPX1, AIFM2 | KMT2A 3080/4885AXL 4570/4885HPGDS 851/4885 |
| US-20220144826-A1 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | AIFM2, FECH, SLC40A1 | KMT2A 2445/4885AXL 1772/4885HPGDS 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.